The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study
Open accessAbstract
Objective: To assess the association between the use of sodium glucose cotransporter 2 (SGLT2) inhibitors and seven serious adverse events of current concern. Design: Register based cohort study. Setting: Sweden and Denmark from July 2013 to December 2016. Participants: A propensity score matched cohort of 17 213 new users of SGLT2 inhibitors (dapagliflozin, 61%; empagliflozin, 38%; canagliflozin, 1%) and 17 213 new users of the active comparator, glucagon-like peptide 1 (GLP1) receptor agonists. Main outcome measures: The primary outcomes were lower limb amputation, bone fracture, diabetic ketoacidosis, acute kidney injury, serious urinary tract infection, venous thromboembolism, and acute pancreatitis, as identified from hospital records. Hazard ratios and 95% confidence intervals were estimated by using Cox proportional hazards models. Results: Use of SGLT2 inhibitors, as compared with GLP1 receptor agonists, was associated with an increased risk of lower limb amputation (incidence rate 2.7 v 1.1 events per 1000 person years, hazard ratio 2.32, 95% confidence interval 1.37 to 3.91) and diabetic ketoacidosis (1.3 v 0.6, 2.14, 1.01 to 4.52) but not with bone fracture (15.4 v 13.9, 1.11, 0.93 to 1.33), acute kidney injury (2.3 v 3.2, 0.69, 0.45 to 1.05), serious urinary tract infection (5.4 v 6.0, 0.89, 0.67 to 1.19), venous thromboembolism (4.2 v 4.1, 0.99, 0.71 to 1.38) or acute pancreatitis (1.3 v 1.2, 1.16, 0.64 to 2.12). Conclusions: In this analysis of nationwide registers from two countries, use of SGLT2 inhibitors, as compared with GLP1 receptor agonists, was associated with an increased risk of lower limb amputation and diabetic ketoacidosis, but not with other serious adverse events of current concern.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
External review and validation of the Swedish national inpatient register
Ludvigsson, J. F., Andersson, E., Ekbom, A., Feychting, M., Kim, J.-L., Reuterwall, C., Heurgren, M., & Olausson, P. O. (2011) · BMC Public Health · doi:10.1186/1471-2458-11-450 · Cited by 5,055
The Danish National Patient Registry: a review of content, data quality, and research potential
Schmidt, M., Schmidt, S. A. J., Sandegaard, J. L., Ehrenstein, V., Pedersen, L., & Sørensen, H. T. (2015) · Clinical Epidemiology · doi:10.2147/clep.s91125 · Cited by 4,769
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Sundbøll, J., Adelborg, K., Munch, T., Frøslev, T., Sørensen, H. T., Bøtker, H. E., & Schmidt, M. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-012832 · Cited by 834
Austin, P. C. (2009) · Biometrical Journal · doi:10.1002/bimj.200810488 · Cited by 769
Lund, J. L., Richardson, D. B., & Stürmer, T. (2015) · Current Epidemiology Reports · doi:10.1007/s40471-015-0053-5 · Cited by 739
8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s008 · Cited by 699
One‐to‐many propensity score matching in cohort studies
Rassen, J. A., Shelat, A. A., Myers, J., Glynn, R. J., Rothman, K. J., & Schneeweiss, S. (2012) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3263 · Cited by 510
Wu, J. H. Y., Foote, C., Blomster, J., Toyama, T., Perkovic, V., Sundström, J., & Neal, B. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00052-8 · Cited by 474
Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus
Watts, N. B., Bilezikian, J. P., Usiskin, K., Edwards, R., Desai, M., Law, G., & Meininger, G. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3167 · Cited by 454
Multiple imputation: review of theory, implementation and software
Harel, O., & Zhou, X. (2007) · Statistics in Medicine · doi:10.1002/sim.2787 · Cited by 427
Effects of sotagliflozin added to insulin in patients with type 1 diabetes
Garg, S. K., Henry, R. R., Banks, P., Buse, J. B., Davies, M. J., Fulcher, G. R., Pozzilli, P., Gesty-Palmer, D., Lapuerta, P., Simó, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708337 · Cited by 417
Handelsman, Y., Henry, R. R., Bloomgarden, Z. T., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Ferrannini, E., Fonseca, V. A., Garber, A. J., Grunberger, G., et al. (2016) · Endocrine Practice · doi:10.4158/ep161292.ps · Cited by 358
Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor
Fralick, M., Schneeweiss, S., & Patorno, E. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1701990 · Cited by 334
Estimating and Using Propensity Scores with Partially Missing Data
D'Agostino, R. B., & Rubin, D. B. (2000) · Journal of the American Statistical Association · doi:10.1080/01621459.2000.10474263 · Cited by 300
Possible adverse effects of SGLT2 inhibitors on bone
Taylor, S. I., Blau, J. E., & Rother, K. I. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70227-x · Cited by 283
Genital and urinary tract infections in diabetes: Impact of pharmacologically-induced glucosuria
Geerlings, S., Fonseca, V., Castro-Diaz, D., List, J., & Parikh, S. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.12.052 · Cited by 274
Bilezikian, J. P., Watts, N. B., Usiskin, K., Polidori, D., Fung, A., Sullivan, D., & Rosenthal, N. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1860 · Cited by 273
Ketoacidosis associated with SGLT2 inhibitor treatment: analysis of FAERS data
Blau, J. E., Tella, S. H., Taylor, S. I., & Rother, K. I. (2017) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2924 · Cited by 271
Risk of fracture with thiazolidinediones: An updated meta-analysis of randomized clinical trials
Zhu, Z.-N., Jiang, Y.-F., & Ding, T. (2014) · Bone · doi:10.1016/j.bone.2014.08.010 · Cited by 253
Udell, J. A., Yuan, Z., Rush, T., Sicignano, N. M., Galitz, M., & Rosenthal, N. (2018) · Circulation · doi:10.1161/circulationaha.117.031227 · Cited by 225
Performance and Limitations of Administrative Data in the Identification of AKI
Grams, M. E., Waikar, S. S., MacMahon, B., Whelton, S., Ballew, S. H., & Coresh, J. (2014) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07650713 · Cited by 198
Kohler, S., Zeller, C., Iliev, H., & Kaspers, S. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0573-0 · Cited by 195
Empagliflozin and Assessment of Lower-Limb Amputations in the EMPA-REG OUTCOME Trial
Inzucchi, S. E., Iliev, H., Pfarr, E., & Zinman, B. (2018) · Diabetes Care · doi:10.2337/dc17-1551 · Cited by 162
Jabbour, S. A., Seufert, J., Scheen, A. J., Bailey, C. J., Karup, C., & Langkilde, A. M. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13124 · Cited by 161
Tahara, A., Takasu, T., Yokono, M., Imamura, M., & Kurosaki, E. (2016) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2016.02.003 · Cited by 148
Zhang, X., Zhu, Q., Chen, Y., Li, X., Chen, F., Huang, J., & Xu, B. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.007165 · Cited by 138
SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System
Fadini, G. P., & Avogaro, A. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30257-7 · Cited by 134
Acute kidney injury from SGLT2 inhibitors: potential mechanisms
Hahn, K. M., Ejaz, A. A., Kanbay, M., Lanaspa, M. A., & Johnson, R. J. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.159 · Cited by 133
Yuan, Ž., DeFalco, F., Ryan, P. B., Schuemie, M. J., Stang, P., Berlin, J. A., Desai, M. G., & Rosenthal, N. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13115 · Cited by 132
Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias?
Suissa, S. (2017) · Diabetes Care · doi:10.2337/dc17-1223 · Cited by 129
Bruun, C., Siersma, V., Guassora, A. D., Holstein, P., & Olivarius, N. D. F. (2013) · Diabetic Medicine · doi:10.1111/dme.12196 · Cited by 127
Tkáč, I., & Raz, I. (2016) · Diabetes Care · doi:10.2337/dc15-1707 · Cited by 120
Perlman, A., Heyman, S. N., Matok, I., Stokar, J., Muszkat, M., & Szalat, A. (2017) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.10.011 · Cited by 97
Ohgaki, R., Wei, L., Yamada, K., Hara, T., Kuriyama, C., Okuda, S., Ueta, K., Shiotani, M., Nagamori, S., & Kanai, Y. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.232025 · Cited by 92
Wang, Y., Desai, M. G., Ryan, P. B., DeFalco, F., Schuemie, M. J., Stang, P., Berlin, J. A., & Yuan, Ž. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.04.004 · Cited by 91
Canagliflozin-induced pancreatitis: a rare side effect of a new drug
Chowdhary, M., Kabbani, A., & Chhabra, A. (2015) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s86641 · Cited by 34
SGLT2 inhibitors and diabetic ketoacidosis — a growing concern
Umpierrez, G. E. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.77 · Cited by 25
Cited by
Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus
Ferguson, D., & Finck, B. N. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00507-z · Cited by 504
SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects
Tentolouris, A., Vlachakis, P., Tzeravini, E., Eleftheriadou, I., & Tentolouris, N. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16162965 · Cited by 300
Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus
Scheen, A. J. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0392-2 · Cited by 267
An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
Salvatore, T., Galiero, R., Caturano, A., Rinaldi, L., Di Martino, A., Albanese, G., Di Salvo, J., Epifani, R., Marfella, R., Docimo, G., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073651 · Cited by 256
Kraus, B. J., Weir, M. R., Bakris, G. L., Mattheus, M., Cherney, D. Z. I., Sattar, N., Heerspink, H. J. L., Ritter, I., von Eynatten, M., Zinman, B., et al. (2021) · Kidney International · doi:10.1016/j.kint.2020.10.031 · Cited by 219
Metadata
- Authors
- Ueda, P., Svanström, H., Melbye, M., Eliasson, B., Svensson, A.-M., Franzén, S., Gudbjörnsdottir, S., Hveem, K., Jonasson, C., & Pasternak, B.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2018-11-14
- Volume
- 363
- Pages
- k4365
- ISSN
- 1756-1833 (ISSN-L)
- 0959-8138
- OpenAlex
- W2900732862
- Cited by
- 367
- References
- 41
- FWCI
- 31.89
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.